Rose is theedalist To received ASTRO Annual Meeting Awards: September 23, 2008The American Society for Therapeutic Radiology, the recipient of the 2008 Gold Medal, the highest award that selected ASTRO awards http://edmdrx.com more info . Christopher Rose, Fastro and Joel Tepper , are with their awards during the 50th ASTRO Annual Meeting in Boston during the Gold Medal Ceremony on Tuesday, September, 00 clock are presented.
It seems especially appropriate that we recognize these two leaders in the field of radiation oncology and former leaders of ASTRO as part of our 50th anniversary Louis Harrison, chairman of the ASTRO Board of Directors and an oncologist said at the Beth Israel Medical Center in New York City. Both leaders have role models for me role models for me and I’m going to great personal pride in a position hand over hand over their medals. Rose is the technical and associate director of Valley Radiotherapy Associates Medical Group, Medical Director of the Center for Radiation Therapy of Beverly Hills, and Chief Technology Officer of Vantage Oncology, He graduated from Harvard Medical School in Boston and has both his internship and residency in internal medicine at Beth Israel Hospital in Boston. Rose finished his residence in radiotherapy at the Joint Center for Radiation Therapy in Boston and a fellowship at the Royal Marsden Hospital in Sutton, in several in several callings, including as a lecturer and assistant professor of radiation oncology at Harvard Medical School as an associate clinical professor of radiation oncology at the University of Southern California in Los Angeles. Rose is a member of several professional societies, including the American Society of Clinical Oncology, the Radiation Research Society and the California Radiation Oncology Society. He is Vice – Chairman of the Quality Research in Radiation Oncology Fellowship of the American College of Radiology. He was named a Fellow of the American College of Radiology in 1993, a fellow of ASTRO in 2006 and was as president of the Southern California Radiation Oncology Society serves, CARROS and ASTRO. Tepper is the Hector MacLean Distinguished Professor of Cancer Research and professor of radiation oncology at the University of North Carolina School of Medicine, where he was president for almost 20 years, he received his bachelor’s degree from MIT, his medical degree from the Washington University School of medicine in St. Louis and completed his internship in internal medicine at Presbyterian-St. Luke’s Hospital in Chicago. Tepper has his residency and fellowship in Radiation Oncology at Massachusetts General Hospital in Boston. He is a member of the American Society of Clinical Oncology, the North Carolina Medical Society, the Radiation Research Society and the American Association for Cancer Research, along with several other professional societies. He was named a Fellow of the ACR fellow of fellow of ASTRO 2006th Tepper served as ASTRO president from 2002-2003 as Chairman of the as Chairman of the Board of Directors. He is currently serving at the ASCO Board of Directors. Tepper major research interests include gastrointestinal tumor, combined. Modality therapy and soft tissue sarcoma He is editor of the seminar in Radiation Oncology, editor of two textbooks, director of the UNC GI SPORE grant and co-chair of the GI Steering Committee of the NCI.
Paper present results of a Phase I clinical single of Moffitt Cancer Center in Tampa, Florida sponsored. , reproducible, and study was designed to use to evaluate that of electrical pulses generated by electroporation Inovio proprietary into tumor cells in tumor cells provide a plasmid DNA, the judge stimulate a cytokine, interleukin-12, the adaptive and innate immunity. The paper concluded: ‘This first human trial, to our knowledge, the gene transfer demonstrated use in vivo electroporation of DNA in metastatic melanoma that safe, effective, reproducible, and titrable is. ‘The results revealed not just the treated regression melanoma cutaneous lesions , but also regression of distant untreated lesions,. To systemic immune response to the localized treatment Daoud Daud, lead investigator of the degree the Moffitt Cancer Center and now Associate Prof., Director of, Melanoma Clinical Research, UCSF Medical Center, said, ‘The fact that more than half of the patients had stabilization or recovery Your melanoma lesions is encouraging. Especially convincing is the regression on untreated tumors, the clinical area. 10 percent of patients with IL-12 and electroporated displays complete regression of the tumor treated either treated and control cancer. Those results have an opens doors about more hopeful of search for a better the treatment of cancers such as melanoma. ‘.